Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting

Kymera Therapeutics announced Phase 1 results for KT-621, a first-in-class oral STAT6 degrader, in healthy Japanese adults at the Japanese Dermatological Association Annual Meeting. The data showed consistent safety and pharmacokinetic/pharmacodynamic profiles with previous studies, demonstrating rapid and sustained STAT6 degradation (≥98% at Day 7). The company has parallel Phase 2b trials ongoing in atopic dermatitis (BROADEN2) and asthma (BREADTH), with data expected by mid-2027 and late 2027, respectively.